Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma –the IT-MATTERS study

• Published in: Pathology oncology research Vol. 31; p. 1612084
• Main Authors: Talor, Eyal, Tímár, József, Lavin, Philip, Cipriano, John, Markovic, Dusan, Ladányi, Andrea, Karpenko, Andrey, Bondarenko, Igor, Stosic, Srboljub, Sobat, Hrvoje, Zhukavets, Aliaksandr, Imamovic, Nazim, Chien, Chih-Yen, Bankowska-Wozniak, Magdalena, Kisely, Mihály, Jovic, Rajko, Young, James Edward Massey, Hao, Sheng-Po
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2025
• Subjects: Adult; Aged; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Female; Follow-Up Studies; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - mortality; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - therapy; Humans; immunotherapy; Immunotherapy - methods; Immunotherapy - mortality; Interleukins - administration & dosage; Interleukins - therapeutic use; Leukocyte interleukin injection (LI); locally advanced disease; low-risk for recurrence; Male; Middle Aged; neoadjuvant; Neoadjuvant Therapy - methods; Neoadjuvant Therapy - mortality; Prognosis; SCCHN; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - mortality; Squamous Cell Carcinoma of Head and Neck - pathology; Squamous Cell Carcinoma of Head and Neck - therapy; Survival Rate; low-risk for recurrence; neoadjuvant; immunotherapy; lower disease burden; SCCHN; Leukocyte interleukin injection (LI); locally advanced disease

The randomized controlled pivotal phase 3 study evaluated efficacy and safety of neoadjuvant complex biologic, Leukocyte Interleukin Injection (LI), administered for 3 consecutive weeks pre-surgery, in treatment naïve resectable locally advanced primary squamous cell carcinoma of oral cavity and sof...